Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Oral medications for gestational diabetes may offer a less expensive and more convenient alternative to insulin, but do they provide better overall value? A new economic analysis of the randomized SUGAR-DIP trial explored this question by comparing medication expenses, healthcare costs, lost productivity, and pregnancy outcomes. The findings suggest that oral treatment may reduce certain societal costs. However, important differences in newborn outcomes mean that lower expenses should not determine treatment decisions alone.
Table of Contents
- Understanding the SUGAR-DIP Cost-Effectiveness Analysis
- Oral Medication vs. Insulin: What Costs Less?
- Maternal and Newborn Outcomes: The Clinical Trade-Off
- What the Findings Mean for Gestational Diabetes Care
- Conclusion
- Frequently Asked Questions
Understanding the SUGAR-DIP Cost-Effectiveness Analysis
The SUGAR-DIP economic analysis, published in BJOG, evaluated whether sequential oral glucose-lowering therapy provides better economic value than insulin for gestational diabetes mellitus (GDM).
Researchers analyzed data from a randomized trial involving 820 pregnant women across 25 hospitals in the Netherlands. Participants had gestational diabetes that remained inadequately controlled with dietary changes.
The trial assigned 409 participants to oral treatment and 411 to insulin. Oral therapy began with metformin, followed by glibenclamide, also called glyburide, when additional glucose control was needed. Insulin could replace glyburide if treatment goals remained unmet.
Importantly, investigators examined costs from both healthcare and societal perspectives. Healthcare expenses included medical visits, treatment, and delivery-related care. Societal costs also considered lost productivity and unpaid support from family members.
Researchers assessed two major outcomes: babies born large for gestational age (LGA) and quality-adjusted life-years (QALYs), a measure combining health and quality of life.
This approach provides a broader picture than comparing prescription prices alone.
Oral Medication vs. Insulin: What Costs Less?
The economic findings suggest that treating gestational diabetes with oral medications may lower certain costs, although the overall savings remain uncertain.
Average unadjusted societal costs were €21,688 per participant in the oral treatment group, compared with €22,713 in the insulin group. In the adjusted primary analysis, the estimated difference was €1,004 less with oral treatment. However, this reduction was not statistically significant.
Lost productivity accounted for much of the observed difference. Participants receiving oral agents had average productivity losses valued at €6,615, compared with €7,574 among those receiving insulin.
Meanwhile, total healthcare costs were nearly identical. Average expenses reached €10,697 with oral therapy and €10,663 with insulin.
The difference in medication expenses was relatively small. Before 36 weeks, gestational diabetes medication costs averaged €4 with oral agents and €12 with insulin, using the study's 2022 euro values.
These figures highlight an important lesson: medication prices represent only a small portion of pregnancy-related spending.
Treatment Burden and Hidden Expenses
Insulin treatment may involve injections, dose adjustments, supplies, and additional patient education. For some patients, these requirements create challenges alongside work and family responsibilities.
Oral medications avoid injections but still require glucose monitoring, follow-up visits, and careful assessment of treatment response. Additionally, some patients need insulin despite starting with tablets.
Earlier research discussed by Diabetes in Control also found greater treatment satisfaction among patients receiving metformin than among those using insulin-based regimens.
Consequently, treatment convenience deserves attention when clinicians discuss patient preferences and daily responsibilities.
Maternal and Newborn Outcomes: The Clinical Trade-Off
Although oral diabetes medications may reduce certain treatment costs during pregnancy, clinicians must also consider maternal and infant safety.
The original SUGAR-DIP randomized clinical trial reported that 23.9% of babies in the oral treatment group were large for gestational age, compared with 19.9% in the insulin group.
This represented an absolute difference of approximately four percentage points. Importantly, oral treatment failed to meet the trial's predefined criteria for noninferiority.
That finding does not establish that oral medications are always less safe. However, it means researchers could not demonstrate that the oral strategy was sufficiently comparable to insulin for this important newborn outcome.
The economic analysis also found a small quality-of-life advantage with oral treatment. The adjusted difference was 0.009 QALYs, approximately three days of perfect health.
While statistically significant, researchers described this improvement as having limited clinical importance.
Furthermore, the original trial reported more maternal hypoglycemia with the sequential oral strategy.
These results demonstrate why lower costs cannot outweigh potential differences in maternal or neonatal outcomes.
Why Insulin Remains the Preferred Treatment
The American Diabetes Association's 2026 Standards of Care continue to recommend insulin as the preferred medication for gestational diabetes when lifestyle measures are insufficient.
Unlike metformin and glyburide, commonly used insulin preparations do not cross the placenta in clinically meaningful amounts.
Metformin and glyburide both cross the placenta, raising concerns about fetal exposure and limited long-term safety information.
Nevertheless, oral agents may be considered in selected circumstances when insulin cannot be used safely or effectively. Such decisions require informed counseling and close monitoring.
What the Findings Mean for Gestational Diabetes Care
The SUGAR-DIP findings offer valuable information for shared decision-making, but they do not support replacing insulin routinely.
First, clinicians should consider whether a patient can achieve pregnancy-specific glucose targets. Medication affordability matters, yet consistent glucose control remains essential.
Second, treatment discussions should address injections, medication tolerance, monitoring supplies, appointment schedules, and access to diabetes education.
Third, clinicians should explain that the study's cost estimates reflect the Dutch healthcare system. Therefore, the results may not translate directly to US insurance coverage, prescription prices, or patient expenses.
Notably, approximately 79% of participants assigned to the oral strategy maintained glucose control without insulin. Some participants required both metformin and glyburide.
However, the economic analysis did not establish that oral therapy improves overall pregnancy outcomes.
For patients considering oral medications to manage gestational diabetes, individualized counseling remains essential. Healthcare professionals can explain treatment alternatives, expected benefits, uncertainties, and potential fetal risks.
Clinical Practice Implications
The study provides three practical lessons for diabetes care teams.
First, evaluating treatment affordability requires more than comparing medication costs. Productivity losses and the wider treatment burden can influence overall economic outcomes.
Second, small quality-of-life gains should be weighed against meaningful neonatal outcomes, especially the risk of large-for-gestational-age births.
Finally, current clinical guidelines and individual patient circumstances should guide medication selection rather than economic estimates alone.
Conclusion
The SUGAR-DIP cost-effectiveness analysis suggests that sequential oral therapy may offer modest societal savings compared with insulin. However, the overall cost difference was not statistically significant, and the oral strategy did not demonstrate noninferiority for preventing large-for-gestational-age births.
For now, insulin remains the preferred pharmacologic treatment for gestational diabetes under US guidelines. Oral treatment may have a role in carefully selected cases, but its lower cost or greater convenience should never replace a thorough assessment of maternal and infant safety.
Frequently Asked Questions
1. Are oral medications for gestational diabetes cheaper than insulin?
The SUGAR-DIP economic analysis found lower average societal costs with oral therapy. However, the difference was not statistically significant, and healthcare costs were similar between groups.
2. Which oral medications were used in the SUGAR-DIP trial?
Researchers used metformin first, added glyburide when necessary, and substituted insulin for glyburide if glucose targets were not achieved. Approximately 79% of patients assigned to oral therapy avoided insulin.
3. Why is insulin preferred for gestational diabetes?
Insulin effectively reduces blood glucose and does not meaningfully cross the placenta. Meanwhile, metformin and glyburide cross the placenta, and uncertainties remain about long-term offspring safety.
4. Does taking oral medication reduce pregnancy complications?
The SUGAR-DIP trial did not demonstrate that its oral treatment strategy was noninferior to insulin for preventing large-for-gestational-age births. Therefore, treatment decisions should consider individual risks and glucose control.
5. Should patients switch from insulin to oral medication to save money?
No patient should change treatment solely because of cost. Clinicians should review glucose readings, pregnancy risks, medication accessibility, and current guidelines before recommending any change.
Disclaimer: This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.